Company news
Quantum Cyber N.V. news in 2024
Quantum Cyber N.V.'s news releases, calls and decks from 2024, newest first.
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
December 18, 2024
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
December 15, 2024
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
December 11, 2024
Mainz Biomed Announces Stock Split
November 28, 2024
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
November 11, 2024
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
October 20, 2024
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
October 7, 2024
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
September 17, 2024
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
September 3, 2024
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
July 24, 2024
Mainz BioMed Seeks FDA Breakthrough Device Designation for Advanced Colorectal Cancer Test
July 18, 2024
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
July 8, 2024
Mainz Biomed Provides Half Year 2024 Corporate Update
July 1, 2024
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
June 2, 2024
Mainz Biomed Reports Results of 2024 Annual General Meeting
May 30, 2024
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
May 27, 2024
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
May 19, 2024
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
May 6, 2024
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
April 24, 2024
Mainz Biomed Reports Full Year 2023 Financial Results
April 8, 2024
Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
March 4, 2024
Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®
February 21, 2024
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
February 20, 2024
Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany
February 5, 2024
Mainz Biomed Provides Year-End Corporate Review 2023
January 8, 2024